vs

Side-by-side financial comparison of EXELIXIS, INC. (EXEL) and EZCORP INC (EZPW). Click either name above to swap in a different company.

EXELIXIS, INC. is the larger business by last-quarter revenue ($598.7M vs $382.0M, roughly 1.6× EZCORP INC). EXELIXIS, INC. runs the higher net margin — 40.8% vs 11.6%, a 29.2% gap on every dollar of revenue. On growth, EZCORP INC posted the faster year-over-year revenue change (19.3% vs 5.6%). EXELIXIS, INC. produced more free cash flow last quarter ($332.4M vs $31.7M). Over the past eight quarters, EXELIXIS, INC.'s revenue compounded faster (18.7% CAGR vs 15.6%).

Exelixis, Inc. is a genomics-based drug discovery company located in Alameda, California, and the producer of Cometriq, a treatment approved by the U.S. Food and Drug Administration (FDA) for medullary thyroid cancer with clinical activity in several other types of metastatic cancer.

EZCORP, Inc. is an American pawn shop operator based in Austin, Texas which provides services across the United States and Latin America. It is a publicly traded company listed on the NASDAQ stock exchange and is the second largest pawn shop operator in the U.S. after Cash America International.

EXEL vs EZPW — Head-to-Head

Bigger by revenue
EXEL
EXEL
1.6× larger
EXEL
$598.7M
$382.0M
EZPW
Growing faster (revenue YoY)
EZPW
EZPW
+13.7% gap
EZPW
19.3%
5.6%
EXEL
Higher net margin
EXEL
EXEL
29.2% more per $
EXEL
40.8%
11.6%
EZPW
More free cash flow
EXEL
EXEL
$300.7M more FCF
EXEL
$332.4M
$31.7M
EZPW
Faster 2-yr revenue CAGR
EXEL
EXEL
Annualised
EXEL
18.7%
15.6%
EZPW

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
EXEL
EXEL
EZPW
EZPW
Revenue
$598.7M
$382.0M
Net Profit
$244.5M
$44.3M
Gross Margin
95.6%
58.4%
Operating Margin
39.3%
15.9%
Net Margin
40.8%
11.6%
Revenue YoY
5.6%
19.3%
Net Profit YoY
74.8%
42.8%
EPS (diluted)
$0.89
$0.55

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
EXEL
EXEL
EZPW
EZPW
Q1 26
$598.7M
Q4 25
$597.8M
$382.0M
Q3 25
$568.3M
$336.8M
Q2 25
$555.4M
$311.0M
Q1 25
$566.8M
$306.3M
Q4 24
$320.2M
Q3 24
$539.5M
$294.6M
Q2 24
$637.2M
$281.4M
Net Profit
EXEL
EXEL
EZPW
EZPW
Q1 26
$244.5M
Q4 25
$193.6M
$44.3M
Q3 25
$184.8M
$26.7M
Q2 25
$159.6M
$26.5M
Q1 25
$139.9M
$25.4M
Q4 24
$31.0M
Q3 24
$118.0M
$15.2M
Q2 24
$226.1M
$17.9M
Gross Margin
EXEL
EXEL
EZPW
EZPW
Q1 26
95.6%
Q4 25
96.9%
58.4%
Q3 25
96.6%
59.0%
Q2 25
96.5%
59.1%
Q1 25
96.5%
58.3%
Q4 24
57.9%
Q3 24
96.8%
59.5%
Q2 24
97.2%
59.2%
Operating Margin
EXEL
EXEL
EZPW
EZPW
Q1 26
39.3%
Q4 25
39.6%
15.9%
Q3 25
37.6%
11.0%
Q2 25
33.6%
11.6%
Q1 25
28.8%
11.2%
Q4 24
13.1%
Q3 24
25.2%
8.8%
Q2 24
43.3%
7.9%
Net Margin
EXEL
EXEL
EZPW
EZPW
Q1 26
40.8%
Q4 25
32.4%
11.6%
Q3 25
32.5%
7.9%
Q2 25
28.7%
8.5%
Q1 25
24.7%
8.3%
Q4 24
9.7%
Q3 24
21.9%
5.2%
Q2 24
35.5%
6.4%
EPS (diluted)
EXEL
EXEL
EZPW
EZPW
Q1 26
$0.89
Q4 25
$0.69
$0.55
Q3 25
$0.65
$0.35
Q2 25
$0.55
$0.34
Q1 25
$0.47
$0.33
Q4 24
$0.40
Q3 24
$0.40
$0.20
Q2 24
$0.77
$0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
EXEL
EXEL
EZPW
EZPW
Cash + ST InvestmentsLiquidity on hand
$1.1B
$465.9M
Total DebtLower is stronger
$518.6M
Stockholders' EquityBook value
$2.2B
$1.1B
Total Assets
$2.8B
$2.0B
Debt / EquityLower = less leverage
0.48×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
EXEL
EXEL
EZPW
EZPW
Q1 26
$1.1B
Q4 25
$988.5M
$465.9M
Q3 25
$791.1M
$469.5M
Q2 25
$1.0B
$472.1M
Q1 25
$1.1B
$505.2M
Q4 24
$174.5M
Q3 24
$1.2B
$170.5M
Q2 24
$1.0B
$218.0M
Total Debt
EXEL
EXEL
EZPW
EZPW
Q1 26
Q4 25
$518.6M
Q3 25
$518.1M
Q2 25
$517.6M
Q1 25
$620.5M
Q4 24
$327.7M
Q3 24
$327.3M
Q2 24
$361.3M
Stockholders' Equity
EXEL
EXEL
EZPW
EZPW
Q1 26
$2.2B
Q4 25
$2.2B
$1.1B
Q3 25
$2.0B
$1.0B
Q2 25
$2.1B
$990.1M
Q1 25
$2.2B
$851.6M
Q4 24
$823.9M
Q3 24
$2.3B
$804.6M
Q2 24
$2.1B
$801.5M
Total Assets
EXEL
EXEL
EZPW
EZPW
Q1 26
$2.8B
Q4 25
$2.8B
$2.0B
Q3 25
$2.7B
$2.0B
Q2 25
$2.8B
$1.9B
Q1 25
$2.9B
$1.8B
Q4 24
$1.5B
Q3 24
$3.0B
$1.5B
Q2 24
$2.8B
$1.5B
Debt / Equity
EXEL
EXEL
EZPW
EZPW
Q1 26
Q4 25
0.48×
Q3 25
0.51×
Q2 25
0.52×
Q1 25
0.73×
Q4 24
0.40×
Q3 24
0.41×
Q2 24
0.45×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
EXEL
EXEL
EZPW
EZPW
Operating Cash FlowLast quarter
$333.5M
$39.1M
Free Cash FlowOCF − Capex
$332.4M
$31.7M
FCF MarginFCF / Revenue
55.5%
8.3%
Capex IntensityCapex / Revenue
0.2%
2.0%
Cash ConversionOCF / Net Profit
1.36×
0.88×
TTM Free Cash FlowTrailing 4 quarters
$875.8M
$121.7M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
EXEL
EXEL
EZPW
EZPW
Q1 26
$333.5M
Q4 25
$290.3M
$39.1M
Q3 25
$49.0M
$51.3M
Q2 25
$211.4M
$34.8M
Q1 25
$240.3M
$36.9M
Q4 24
$26.0M
Q3 24
$271.3M
$43.3M
Q2 24
$119.5M
$33.7M
Free Cash Flow
EXEL
EXEL
EZPW
EZPW
Q1 26
$332.4M
Q4 25
$288.8M
$31.7M
Q3 25
$46.2M
$35.7M
Q2 25
$208.5M
$25.7M
Q1 25
$236.3M
$28.6M
Q4 24
$20.4M
Q3 24
$263.1M
$24.4M
Q2 24
$113.0M
$30.5M
FCF Margin
EXEL
EXEL
EZPW
EZPW
Q1 26
55.5%
Q4 25
48.3%
8.3%
Q3 25
8.1%
10.6%
Q2 25
37.5%
8.3%
Q1 25
41.7%
9.3%
Q4 24
6.4%
Q3 24
48.8%
8.3%
Q2 24
17.7%
10.8%
Capex Intensity
EXEL
EXEL
EZPW
EZPW
Q1 26
0.2%
Q4 25
0.2%
2.0%
Q3 25
0.5%
4.6%
Q2 25
0.5%
2.9%
Q1 25
0.7%
2.7%
Q4 24
1.8%
Q3 24
1.5%
6.4%
Q2 24
1.0%
1.1%
Cash Conversion
EXEL
EXEL
EZPW
EZPW
Q1 26
1.36×
Q4 25
1.50×
0.88×
Q3 25
0.27×
1.92×
Q2 25
1.32×
1.31×
Q1 25
1.72×
1.45×
Q4 24
0.84×
Q3 24
2.30×
2.85×
Q2 24
0.53×
1.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

EXEL
EXEL

Cabometyx$544.7M91%
Collaboration$52.1M9%
Collaborative Arrangementwith Takeda$5.9M1%
Cometriq$1.8M0%

EZPW
EZPW

Merchandise$210.1M55%
Pawn Service$131.9M35%
Jewelry Scrap$39.9M10%

Related Comparisons